- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Alzheimer's disease
Lilly study: 1 in 5 Alzheimer's patients misdiagnosed
May 20, 2013
J.K. WallThe study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare
to pay for use of its brain imaging agent Amyvid.
MoreLilly suing J&J for patent rights in Alzheimer's drug race
April 25, 2013
Bloomberg NewsEli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay
availability of a potential treatment for Alzheimer’s disease.
MoreNew $100M plan to map human brain could boost Lilly
April 2, 2013
Bloomberg NewsPresident Obama on Tuesday announced a campaign designed to develop treatments for some of the least understood brain disorders,
an effort that could benefit health care giants Eli Lilly and Co. and others.
MoreLilly's Alzheimer’s effort may gain from brain-mapping plan
February 18, 2013
Bloomberg NewsRoche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders,
may gain the most from a U.S. government boost in funding to fully map the human brain.
MoreLilly drug chosen for Alzheimer's prevention study
January 18, 2013
Associated PressResearchers have chosen an experimental drug by Eli Lilly and Co. for a large federally funded study testing whether it's
possible to prevent Alzheimer's disease in older people at high risk of developing it.
MoreLilly's Amyvid receives European approval
January 16, 2013
Associated PressEuropean regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's
disease.
MoreLilly finds solace in new Alzheimer's study
December 17, 2012
J.K. WallEli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published
new research that the pharmaceutical company thinks confirms it is on the right track.
MoreAlzheimer’s prevention seen promising as drug cures fail
October 19, 2012
Bloomberg NewsResearchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts
to find a cure have been unsuccessful.
MoreLilly, Roche drugs chosen for Alzheimer’s prevention trial
October 10, 2012
Bloomberg NewsEli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s
trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
MoreLilly shares rise on Alzheimer's study results
October 8, 2012
J.K. WallEli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease,
according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than
5 percent on the news.
MoreNew Alzheimer's unit stresses soothing elements
October 6, 2012
Scott OlsonThe 36-room wing at Hoosier Village Retirement Center includes antiques and minimizes confusing shadows among other design
elements.
MoreLilly's Alzheimer's finding triggers investor hope, doctor caution
August 27, 2012
Bloomberg NewsWhile investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression
early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
MoreAlzheimer's drug results leave Lilly 'excited' but uncertain
August 24, 2012
J.K. WallThe surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly
and Co., but it raised as many questions as it answered.
MoreLilly's Alzheimer's drug trials show mixed results
August 24, 2012
Bloomberg News, J.K. WallEli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials.
However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some
patients.
MoreAlzheimer's quest puts Lilly to test
August 11, 2012
J.K. WallOdds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results
are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a
home run for Lilly.
MoreLilly stock slips after competitors halt Alzheimer's plans
August 7, 2012
IBJ Staff and Bloomberg NewsPfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second
trial failure. Eli Lilly is developing a similar treatment.
MorePotential Alzheimer’s drug fails first of four key trials
July 24, 2012
Bloomberg NewsBapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to
target a cause for Alzheimer’s, rather than just its symptoms.
MoreCompeting Alzheimer's treatments facing long odds
July 11, 2012
Bloomberg NewsJohnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available
drug designed to target a cause of Alzheimer's, rather than just its symptoms. Analysts say the potential drugs are long shots.
MoreCancer tools help Roche with Alzheimer's drug
May 13, 2012
Bloomberg NewsTreatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may
pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs
that attack the same protein as Roche’s experimental drug.
MoreLilly: Forget Alzheimer's; think diabetes
May 7, 2012
J.K. WallFor more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a
huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward
the drugmaker’s diabetes portfolio.
MoreLilly wins FDA approval for Alzheimer's imaging agent
April 9, 2012
J.K. WallThe agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with
Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
MoreLilly shares rise on possibility for Alzheimer’s drug
December 7, 2011
Bloomberg NewsEli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s
experimental Alzheimer’s drug could double the share price.
MoreIU med school gets $9M for Alzheimer's center
November 1, 2011
J.K. WallThe grant is the fifth consecutive five-year grant the Alzheimer Disease Center has received from NIH to support research
to understand the causes and potential treatments for Alzheimer’s and other forms of dementia.
MoreLilly fights view that fate hinges on Alzheimer's drug
October 29, 2011
Greg AndrewsAnalysts have eyes on trial data for drug that could be a game-changer for the company.
MoreIU Alzheimer's study to be funded by $8.4M federal grant
October 10, 2011
J.K. WallRemaining grant money will be invested to beef up the infrastructure of the Indiana Network for Patient Care, a health information
exchange operated by the Indianapolis-based Regenstrief Institute.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
liek the rest of America
These quaint,obsessed musings by the stalkers are certainly entertaining, but I'm trying to figure out what, if anything, all the yelping below has to do with Zak Brown.
It's evident that Moffett was pushing the right buttons and corporate America is now trying to squash him. He just wanted to withdraw the free pilot services provided to the company by the pilots to try and put some pressure on a company that has not been interested in negotiating a contract in over 5 years. The company does not provide a contract because not having one has saved them a bundle of money. Shame on any Republic pilots not standing behind their union leader just because things are getting tough, can you not see such strategic moves by the company as putting the last union president in a corporate position and into THEIR pocket. Do you really believe the last union president is so appalled at the attempts by Moffett, do you not remember his oppositions to the company? We stood behind him. It has been proven over and over again for thousands of years without fail, a man cannot serve two masters. Anyone that believes people vote contrary to their paycheck and livelihood deserve to be taken advantage of, the recent statements by the former union president are laughable as he denounces the current union president from his new corporate position. Have you ever seen a drafted sports player score points for his previous team, it cannot be done, he is not on the pilots side anymore, he gets his money a different way now than you and I do, and he should not be allowed to remain on the seniority list. A drafted player brings strength, credibility, tactical knowledge, and a strategic advantage to his NEW team, he would not be drafted or paid were it otherwise. We are all forced to choose only one side to play for and support, not doing so has many references in life such as insider trading and shaving points, all illegal for good reason. This basic fact is why corporate moguls, scientist, and engineers all sign non-discloser agreements and non-compete clauses, as protection in case they are lured into switching sides as our former union president has done. No NFL coach ever drafted a player so that both teams could benefit and better understand each other, they are recruited to win the game against that former team, period. Likewise the company does not recruit the former union president by accident or mutual understanding, its strategy. Don't confuse playing the game with good sportsman-like conduct in support of common business and prosperity goals, with the requirement to only play for one side. Good men we all love and favor fall subject to this manipulation, often without their knowledge, and it is not a betrayal of their friendship to oppose them when they switch sides. If we did not love and trust them, they would not have been chosen and lured to the other side in the first place. The deception by the drafted player is not made at a conscious level, it's just human nature and it's all about money and power which corrupts our ability to be objective and loyal to two masters. This is why our court system created the defense attorney, and why our military created counter intelligence. Its strategy and its propaganda, and it works, and that's why the "powers to be" manipulate the chess pieces by sometimes changing their colors. Some players know they are being manipulated when their color is changed, but it brings them more money and power so they do not care. The rest have good intentions but do not even realize they are being manipulated. This tactic is also known by another name, Divide and Conquer. In battle sending an imperfect message with an imperfect team is obviously not ideal, but it's still being sent by YOUR team, your union leader, a leader that has common goals and common rewards with you, they are the best, because we have elected them to do a job for us. If you are not backing Moffett but believing the spin by those that have recently switched sides, you are taking food out of your own mouth. Showing unity and backing an imperfect situation still results in taking just as much ground, it's about unity and bargaining power. It's not necessary to wait around for that perfect attack because it will never come, the company will spin and attempt to destroy anyone that gets in their way. Ultimately it's not about any specific attack anyway, ASAP or whatever it makes no difference, it is and always has been only about power. If this company cared about safety it would not build pairings with 8 hour overnights, come on, are you that naive? Besides, do you really think Hoffa cares, no, he got a call from corporate America and was squeezed into denouncing Moffett. If he didn't they would spin the safety card against him and the Teamsters National with implication for truckers, future contracts, insurance rates etc...saying something like the Teamsters use safety as a bargaining chip, blah blah blah... Do you really think any pilot is going to do something unsafe for the contract, absolutely not, the only ones threatening safety here is the company with reduced rest, fatigue, and poverty. Do you not find it odd that Hoffa and the Teamsters are opposing a Teamster president publicly? Would the Teamsters National not normally support and work with one of their own? Why did they not sit down and help him strategize, correct any mistakes, and charge ahead? Would the Teamsters National not normally support and leverage a contract for all those pilots that have been paying Teamster dues, isn't that why we have all been paying Teamster dues in the first place? I sure haven't been paying dues so that the Teamsters National could come along and write this kind of an article undercutting our union leader and our unity. Whose side is the Teamsters National really on, it's obviously not the Republic pilots side.
No matter what Moffatt does the company is going to spin it like he is the terrorist and brainwash people like you into believing it, wake up, back your players that are trying to change things for you and your livelihood. Where has Hoffa been for the last 6 years, except collecting our dues. Seriously, do you really think an FO going for upgrade, signed off by a checkairman ready for the upgrade, who then fails, is not even capable of returning as a First Officer.
whoa!